Table 1.
Inocula, attack rates, incubation periods and templated PrPD types following transmission of sCJDMM2, sporadic and familial fatal insomnia to TgGlyc+ and TgGlyc− mice
| TgGlyc+ | TgGlyc− | ||||
|---|---|---|---|---|---|
| Inoculum | Attack rate | Incubation period (dpi)a | Inoculum | Attack rate | Incubation period (dpi)a |
| sCJDMM2 | sCJDMM2 | ||||
| First passage Ab | 5/6 | 557 ± 56 | First passage A, B and Cb | 6/6; 9/10; 8/8 | 279 ± 5; 250 ± 70; 274 ± 12 |
| First passage Bb | 5/7 | 582 ± 142 | Second passage | 8/8 | 78 ± 0 |
| — | T2c: 3/7 | 695 ± 81 | Third passage | 10/10 | 77 ± 8 |
| — | T1c: 4/7 | 503 ± 62 | |||
| Sporadic fatal insomnia | Sporadic fatal insomnia | ||||
| First passage | 5/5 | 612 ± 40 | First passage A and Bb | 7/8; 4/7 | 260 ± 20; 497 ± 49 |
| Second passage A and Bb | 7/7; 7/7 | 77 ± 10; 227 ± 9 | |||
| Third passage | 11/11 | 76 ± 5 | |||
| Familial fatal insomnia | Familial fatal insomnia | ||||
| First passage | 0/11 | 791 ± 31e | First passage | 3/10 | 289 ± 13 |
| TgGlyc− adaptedd | 0/8 | 667 ± 87e | Second passage | 8/8; 7/7 | 79 ± 11; 306 ± 19 |
| Drowsy and hyperactive | 0/4 and 0/8 | 720 ± 144e; 676 ± 123e | |||
| None | 0/6 | 713 ± 80e; 618–832f | |||
sCJDMM2 = sporadic Creutzfeldt–Jakob disease subtype MM2.
The incubation period is expressed as mean days post-inoculation (dpi) ± standard deviation (SD).
bThe passages indicated as A, B or C throughout the table were carried out inoculating homogenates from distinct human cases at first passage or from distinct positive transgenic (Tg) mice at second and third passages.
cT (type) 1 and 2 of disease-related prion protein (PrPD) is based on western blot examinations.
dInoculum from a positive familial fatal insomnia-inoculated TgGlyc− mouse.
eLifespan average ± SD.
fLifespan range of uninoculated TgGlyc− mice.